<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) April 30, 1998
--------------
BOSTON LIFE SCIENCES, INC.
--------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-6533 87-0277826
- -------------------------------- ------- --------------------------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File No.) Identification No.)
31 Newbury Street, Suite 300
Boston, Massachusetts 02116
- ------------------------------------------ --------------------------------
(Address of principal executive offices) Zip Code
Registrant's telephone number, including area code (617) 425-0200
---------------
<PAGE>
Item 5. Other Events.
-------------
Boston Life Sciences, Inc. announced that the results of a physician's sponsored
Phase I/II study of Altropane, currently under development by BLSI, have been
published in the neuroscience journal Synapse (vol. 29). In addition to the
article describing the results of this Phase I/II study, three additional
articles relating to the usefulness of Altropane as a SPECT or PET imaging agent
for the diagnosis of Parkinson's Disease were published in the same issue of
Synapse.
In the Phase I/II study, seven healthy volunteers and eight patients with early
or moderate PD underwent SPECT scanning one hour after injection of Altropane.
The article noted that Altropane accumulated rapidly and selectively in the
striatum of the healthy volunteers,and yielded excellent quality images within
one hour after injection. Furthermore, in all the PD patients, striatal
accumulation was markedly reduced. The reduction in striatal Altropane uptake
in PD was statistically significantly reduced compared to healthy volunteers
(p less than 0.001). The conclusion of the authors was that in the future, this
technique is likely to be of considerable value for detecting early PD, probing
the fundamental pathophysiology of the disease, and for monitoring the effects
of new and novel medical and surgical therapies.
The three additional articles, entitled "Altropane, a SPECT or PET Imaging Probe
for Dopamine Neurons, I, II, and III" document the pre-clinical scientific work
performed by scientists at Harvard Medical School and Organix, Inc., which
supports the potential of Altropane as a clinically useful SPECT imaging agent.
The Company views the publication of these four articles as indicative of the
scientific and potential clinical importance of this product and hopes to
confirm the Phase I/II results in its Phase III study, which is designed to test
the hypothesis that Altropane-SPECT scanning can reliably differentiate early PD
from other movement disorders.
BLSI is developing novel treatments for cancer, autoimmune diseases, and central
nervous system disorders.
Item 7. Exhibits.
--------
The following Exhibits are filed as part of this report on Form 8-K:
99.1 Press Release, dated April 30, 1998.
1
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto authorized.
BOSTON LIFE SCIENCES, INC.
Dated: May 7, 1998 By: /s/ Joseph Hernon
-----------------
Joseph Hernon
Chief Financial Officer
2
<PAGE>
BOSTON LIFE SCIENCES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
Exhibit No. Page(s)
- ----------- -------
99.1 Press Release, dated April 30, 1998 4
3
<PAGE>
Exhibit 99.1
FOR IMMEDIATE RELEASE
BOSTON LIFE SCIENCES ANNOUNCES THE PUBLICATION OF THE RESULTS OF PHASE I/II
STUDY OF ALTROPANE FOR THE DIAGNOSIS PF PARKINSON'S DISEASE
BOSTON, MA, APRIL 30, 1998. BOSTON LIFE SCIENCES, INC. (NASDAQ: BLSI) announced
that the results of physician's sponsored Phase I/II study of Altropane
(currently under development by BLSI) have been published in the current issue
of the neuroscience journal Synapse (vol. 29). In addition to the article
describing the results of this Phase I/II study, three additional articles
relating to the usefulness of Altropane as a SPECT or PET imaging agent for the
diagnosis of Parkinson's Disease (PD) were published in the same issue of
Synapse.
In the clinical Phase I/II study, seven healthy volunteers and eight patients
with early or moderate PD underwent SPECT scanning one hour after injection of
Altropane. The summary abstract of the article in Synapse states: "In the
healthy volunteers, Altropane accumulated rapidly and selectively in the
striatum and yielded excellent quality images within one hour after
injection...In all the PD patients, striatal accumulation was markedly
reduced..." The reduction in striatal Altropane uptake in PD was statistically
significantly reduced compared to healthy volunteers (p less than 0.001). The
authors conclude "...In the future, this technique is likely to be of
considerable value for detecting early PD, probing the fundamental
pathophysiology of the disease, and for monitoring the effects of new and novel
medical and surgical therapies."
The three additional articles, entitled "Altropane, a SPECT or PET Imaging Probe
for Dopamine Neurons, I, II, and III" document the pre-clinical scientific work
performed by scientists at Harvard Medical School and Organix, Inc., which
supports the potential of Altropane as a clinically useful SPECT imaging agent.
"We believe that the simultaneous publication of these four articles in Synapse
is indicative of the scientific and potential clinical importance of this
product", stated Marc E. Lanser, MD, Chief Scientific Officer of BLSI. "We hope
to confirm these encouraging results in our Phase III study, which we have
designed to test the hypothesis that Altropane-SPECT scanning can reliably
differentiate early PD from other movement disorders", added Dr. Lanser.
BLSI is developing novel treatments for cancer, autoimmune diseases, and central
nervous system disorders. In addition to Altropane, BLSI's products in clinical
trials or in preclinical development include Troponin I, a natural anti-
angiogenesis factor for the treatment of solid tumors; Therafectin, an oral drug
for the treatment of Rheumatoid Arthritis; Axogenesis Factor 1 (AF1), a Central
Nervous System (CNS) growth factor for the treatment of stroke and spinal cord
injuries; and transcription factors that may control the expression of molecules
associated with autoimmune disease and allergies.
For additional information contact:
Marc E. Lanser, MD
Chief Scientific Officer
617-425-0200
4
